Lv1
20 积分 2025-09-13 加入
Tarlatamab: First Approval
7个月前
已完结
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial
7个月前
已关闭
Efficacy Outcomes Between Tarlatamab and Real-World Physicians’ Choice of Therapies for Previously Treated Extensive Stage Small Cell Lung Cancer
7个月前
已完结
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
7个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
7个月前
已完结
Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer
7个月前
已完结
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
7个月前
已完结
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
8个月前
已完结
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
8个月前
已完结
Endothelial CDS2 deficiency causes VEGFA-mediated vascular regression and tumor inhibition
8个月前
已完结
皖公网安备34019202002308
